For example, TOB1 predicted the prognosis in KIRC, LGG, MESO, PAAD, PCPG, PRAD, SARC, UCEC and UVM patients, and TOB2 predicted poor prognosis in COAD, GBM, KIRC, LGG, PAAD patients. Here, TOB2 is linked to prostate adenocarcinoma.